Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Konstantinopoulos, Panagiotis A.; Ceccaldi, Raphael; Shapiro, Geoffrey I.; D'Andrea, Alan D.

doi:10.1158/2159-8290.cd-15-0714

Cited by 946PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Open access

Konstantinopoulos, Panagiotis A., Ceccaldi, Raphael, Shapiro, Geoffrey I., D'Andrea, Alan D.·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-15-0714PMC PMC4631624

Open this paper in CoChat — free account

Abstract

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway genes. Defective HR is an important therapeutic target in EOC as exemplified by the efficacy of platinum analogues in this disease, as well as the advent of PARP inhibitors, which exhibit synthetic lethality when applied to HR-deficient cells. Here, we describe the genotypic and phenotypic characteristics of HR-deficient EOCs, discuss current and emerging approaches for targeting these tumors, and present challenges associated with these approaches, focusing on development and overcoming resistance. Significance: Defective DNA repair via HR is a pivotal vulnerability of EOC, particularly of the high-grade serous histologic subtype. Targeting defective HR offers the unique opportunity of exploiting molecular differences between tumor and normal cells, thereby inducing cancer-specific synthetic lethality; the promise and challenges of these approaches in ovarian cancer are discussed in this review. Cancer Discov; 5(11); 1137–54. ©2015 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-0714

Cites

178 of 178 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

HR deficiency tumors are more likely to be highly sensitive to platinum-based chemotherapy.
“Increasing evidence suggests that tumors with HR deficiency are more likely to be highly sensitive to platinum-based chemotherapy20–22.”
From Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy (2019) · cites this paper as [20]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854 · see citing works
Cancer statistics, 2013
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825 · see citing works
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · see citing works
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733 · see citing works
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · see citing works
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798 · see citing works
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626 · see citing works
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · see citing works
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229 · see citing works
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,217 · see citing works
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke‐Pearson, D. L., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. N. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,034 · see citing works
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,891 · see citing works
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671 · see citing works
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,551 · see citing works
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,437 · see citing works
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B. T., & Mills, G. B. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2644 · Cited by 1,353 · see citing works
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311 · see citing works
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · see citing works
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
Gordon, A. N., Fleagle, J., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, Á. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,212 · see citing works
Role of poly(ADP-ribose) formation in DNA repair
Satoh, M. S., & Lindahl, T. L. (1992) · Nature · doi:10.1038/356356a0 · Cited by 1,181 · see citing works
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Alsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,179 · see citing works
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Gelmon, K. A., Tischkowitz, M. D., MacKay, H. J., Swenerton, K. D., Robidoux, A., Tonkin, K. S., Hirte, H. W., Huntsman, D. D., Clemons, M. J., Gilks, C. B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117 · see citing works
Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications
Polo, S. E., & Jackson, S. P. (2011) · Genes & Development · doi:10.1101/gad.2021311 · Cited by 1,092 · see citing works
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086 · see citing works
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051 · see citing works
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,050 · see citing works
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · see citing works
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Fong, P. C. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui‐Roelvink, M., Gourley, C., Grève, J. D., Lubiński, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,009 · see citing works
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001 · see citing works
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979 · see citing works
MMEJ repair of double-strand breaks (director’s cut): deleted sequences and alternative endings
McVey, M., & Lee, S. E. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.08.007 · Cited by 974 · see citing works
Cancer of the ovary.
Cannistra, S. (1993) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 957 · see citing works
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Rottenberg, S., Jaspers, J. E., Kersbergen, A. J., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 954 · see citing works
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A., Roeb, W., Agnew, K. J., Stray, S. M., Wickramanayake, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115052108 · Cited by 929 · see citing works
XRCC1 Is Specifically Associated with Poly(ADP-Ribose) Polymerase and Negatively Regulates Its Activity following DNA Damage
Masson, M., Niedergang, C., Schreiber, V., Muller, S., Murcia, J. M., & de MURCIA, G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.6.3563 · Cited by 910 · see citing works
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Ceccaldi, R., Liu, J., Amunugama, R., Hajdú, I., Primack, B., Petalcorin, M. I. R., O’Connor, K. W., Konstantinopoulos, P. A., Elledge, S. J., Boulton, S. J., et al. (2015) · Nature · doi:10.1038/nature14184 · Cited by 908 · see citing works
Self-citation
A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice
Escribano‐Diaz, C., Orthwein, A., Fradet‐Turcotte, A., Xing, M., Young, J. T. F., Tkáč, J., Cook, M. A., Rosebrock, A. P., Munro, M., Canny, M. D., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.001 · Cited by 903 · see citing works
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P. G., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896 · see citing works
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
Winter, W. E., Maxwell, G. L., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M. M., Armstrong, D. K., Muggia, F. M., & McGuire, W. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2517 · Cited by 844 · see citing works
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Wang, M., Wu, W., Wu, W., Rosidi, B., Zhang, L., Wang, H., & Iliakis, G. E. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl840 · Cited by 823 · see citing works
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
Abkevich, V., Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith‐McCune, K., Broaddus, R. R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 818 · see citing works
Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
Mateos‐Gómez, P. A., Gong, F., Nair, N., Miller, K. M., Denchi, E. L., & Sfeir, A. J. (2015) · Nature · doi:10.1038/nature14157 · Cited by 758 · see citing works
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
Pfisterer, J., Plante, M., Vergote, I. B., du Bois, A., Hirte, H. W., Lacave, Á. J., Wagner, U. A. G., Staehle, A., Stuart, G. C. E., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 752 · see citing works
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene
Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., Freund, M., Lichtner, P., Hartmann, L., Schaal, H., et al. (2010) · Nature Genetics · doi:10.1038/ng.569 · Cited by 743 · see citing works
Involvement of Poly(ADP-ribose) Polymerase-1 and XRCC1/DNA Ligase III in an Alternative Route for DNA Double-strand Breaks Rejoining
Audebert, M., Salles, B., & Calsou, P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404524200 · Cited by 709 · see citing works
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J. V., ARANGO, H. A., LaPolla, J. P., Hoffman, M. S., Martino, M. A., Wakeley, K., et al. (2005) · Cancer · doi:10.1002/cncr.21536 · Cited by 690 · see citing works
Exploring the Genomes of Cancer Cells: Progress and Promise
Stratton, M. R. (2011) · Science · doi:10.1126/science.1204040 · Cited by 688 · see citing works
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
Popova, T. G., Manié, É., Rieunier, G., Caux‐Moncoutier, V., Tirapo, C., Dubois, T., Delattre, O., Sigal‐Zafrani, B., Bollet, M. A., Longy, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1470 · Cited by 666 · see citing works
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 644 · see citing works
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Birkbak, N. J., Wang, Z. C., Kim, J.-Y., Eklund, A. C., Li, Q., Tian, R., Bowman-Colin, C., Li, Y., Greene-Colozzi, A., Iglehart, J. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0206 · Cited by 641 · see citing works
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y. H., & Yu, A. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 633 · see citing works
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T. A., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 630 · see citing works
RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection
Chapman, J. R., Barral, P., Vannier, J., Borel, V., Steger, M., Tomás‐Loba, A., Sartori, A. A., Adams, I. R., Batista, F. D., & Boulton, S. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.002 · Cited by 624 · see citing works
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres‐Lockhart, K., Prat, A., Antón, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 609 · see citing works
Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Yang, D., Khan, S., Sun, Y., Hess, K., Shmulevich, I., Sood, A. K., & Zhang, W. (2011) · JAMA · doi:10.1001/jama.2011.1456 · Cited by 599 · see citing works
53BP1 Regulates DSB Repair Using Rif1 to Control 5′ End Resection
Zimmermann, M., Lottersberger, F., Buonomo, S. B. C., Sfeir, A. J., & de Lange, T. (2013) · Science · doi:10.1126/science.1231573 · Cited by 594 · see citing works
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Xu, G., Chapman, J. R., Brandsma, I., Yuan, J., Mistrík, M., Bouwman, P., Bártková, J., Gogola, E., Warmerdam, D. O., Barazas, M., et al. (2015) · Nature · doi:10.1038/nature14328 · Cited by 594 · see citing works
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Liu, J. F., Barry, W. T., Birrer, M. J., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B. J., Buss, M. K., Nattam, S. R., Hurteau, J. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 583 · see citing works
Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Norquist, B. M., Wurz, K., Pennil, C. C., Garcia, R. L., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577 · see citing works
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
Boyd, J., Sonoda, Y., Federici, M. G., Bogomolniy, F., Rhei, E., Maresco, D., Saigo, P., Almadrones, L., Barakat, R., Brown, C., et al. (2000) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.283.17.2260 · Cited by 570 · see citing works
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C. J., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H. W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 546 · see citing works
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 543 · see citing works
Germline mutations in RAD51D confer susceptibility to ovarian cancer
Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J. R., Bowden, G. R., Kalmyrzaev, B., Warren-Perry, M., Snape, K. M. G., et al. (2011) · Nature Genetics · doi:10.1038/ng.893 · Cited by 530 · see citing works
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B. S., DeFelice, M. T., Pochanard, P., Ducar, M. D., Hummelen, P. V., MacConaill, L. E., Hahn, W. C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0184 · Cited by 526 · see citing works
Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer
Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., Mazoyer, S., Chenevix-Trench, G., Easton, D. F., Antoniou, A. C., et al. (2015) · JAMA · doi:10.1001/jama.2014.5985 · Cited by 521 · see citing works
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A. J., Boon, U., Sol, W., van Deemter, L., Zander, S. A. L., Drost, R., Wientjens, E., Ji, J. J., Aly, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 515 · see citing works
DNA topoisomerase-targeting antitumor drugs can be studied in yeast.
Nitiss, J. L., & Wang, J. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.20.7501 · Cited by 503 · see citing works
Saccharomyces cerevisiae Ku70 potentiates illegitimate DNA double‐strand break repair and serves as a barrier to error‐prone DNA repair pathways.
Boulton, S. J., & Jackson, S. P. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00890.x · Cited by 502 · see citing works
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
Vos, M. D., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 491 · see citing works
Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N. J., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 480 · see citing works
Self-citation
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465 · see citing works
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N. D., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457 · see citing works
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Lord, C. J., & Ashworth, A. (2013) · Nature Medicine · doi:10.1038/nm.3369 · Cited by 456 · see citing works
Modernizing the Nonhomologous End-Joining Repertoire: Alternative and Classical NHEJ Share the Stage
Deriano, L., & Roth, D. B. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-110711-155540 · Cited by 448 · see citing works
Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial
Markman, M. M., Liu, P., Wilczynski, S. P., Monk, B. J., Copeland, L. J., Alvarez, R. D., Jiang, C. S., & Alberts, D. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.013 · Cited by 447 · see citing works
Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins
Ahel, I., Ahel, D., Matsusaka, T., Clark, A. J., Pines, J., Boulton, S. J., & West, S. C. (2008) · Nature · doi:10.1038/nature06420 · Cited by 429 · see citing works
miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
Moskwa, P., Buffa, F. M., Pan, Y., Panchakshari, R. A., Gottipati, P., Muschel, R. J., Beech, J. S., Kulshrestha, R., Abdelmohsen, K., Weinstock, D. M., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.12.005 · Cited by 428 · see citing works
EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer
Hughes‐Davies, L., Huntsman, D. D., Ruas, M., Fuks, F., Bye, J. M., Chin, S., Milner, J., Brown, L. A., Hsu, F. D., Gilks, C. B., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00930-9 · Cited by 422 · see citing works
Unrepaired DNA Breaks in p53-Deficient Cells Lead to Oncogenic Gene Amplification Subsequent to Translocations
Zhu, C., Mills, K. D., Ferguson, D. O., Lee, C., Manis, J., Fleming, J., Gao, Y., Morton, C. C., & Alt, F. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00770-5 · Cited by 421 · cited 1× · see citing works
“Early evidence for alt-EJ came from studies in yeast and mammalian cells deficient in C-NHEJ that were still able to repair DSBs via end joining (113, 114) and by the observation that mice deficient in C-NHEJ still exhibited chromosomal translocations and V(D)J recombination (115, 116).”
Background
Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Timms, K. M., Abkevich, V., Hughes, E., Neff, C. D., Reid, J., Morris, B., Kalva, S., Potter, J., Tran, T. V., Chen, J., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0475-x · Cited by 418 · see citing works
Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes
Gagné, J., Isabelle, M., Lo, K. S., Bourassa, S., Hendzel, M. J., Dawson, V. L., Dawson, T. M., & Poirier, G. G. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn771 · Cited by 416 · see citing works
Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching
Virgilio, M. D., Callén, E., Yamane, A., Zhang, W., Janković, M., Gitlin, A. D., Feldhahn, N., Resch, W., Oliveira, T. Y., Chait, B. T., et al. (2013) · Science · doi:10.1126/science.1230624 · Cited by 401 · see citing works
Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
D’Andrea, A. D. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0809889 · Cited by 380 · see citing works
Self-citation
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373 · see citing works
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
Hennessy, B. T., Timms, K. M., Carey, M. S., Gutin, A., Meyer, L. A., Flake, D. D., Abkevich, V., Potter, J., Pruss, D., Glenn, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2997 · Cited by 372 · see citing works
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 356 · see citing works
53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions
Callén, E., Virgilio, M. D., Kruhlak, M. J., Nieto-Soler, M., Wong, N., Chen, H. T., Faryabi, R. B., Polato, F., Santos, M. A., Starnes, L. M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.023 · Cited by 346 · see citing works
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, L. J., Sandhu, S. K., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 337 · see citing works
DNA Ligase III as a Candidate Component of Backup Pathways of Nonhomologous End Joining
Wang, H., Rosidi, B., Perrault, A. R., Wang, M., Zhang, L., Windhofer, F., & Iliakis, G. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3055 · Cited by 334 · see citing works
Mechanism of Microhomology-Mediated End-Joining Promoted by Human DNA Polymerase Theta
Kent, T., Chandramouly, G., McDevitt, S., Ozdemir, A. Y., & Pomerantz, R. (2015) · Nature Structural &Molecular Biology · doi:10.1038/nsmb.2961 · Cited by 331 · see citing works
Rag mutations reveal robust alternative end joining
Corneo, B., Wendland, R. L., Deriano, L., Cui, X., Klein, I. A., Wong, S.-Y., Arnal, S. M., Holub, A. J., Weller, G. R., Pancake, B. A., et al. (2007) · Nature · doi:10.1038/nature06168 · Cited by 331 · see citing works
Involvement of poly(ADP-ribose) polymerase in base excision repair
Dantzer, F., Schreiber, V., Niedergang, C., Trucco, C., Flatter, E., de la Rubia, G., Oliver, J., Rolli, V., Murcia, J. M., & de MURCIA, G. (1999) · Biochimie · doi:10.1016/s0300-9084(99)80040-6 · Cited by 327 · see citing works
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 326 · see citing works
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin, R. L., Nemeth, E., Tran, H., Shvartsman, H. S., Cass, I. A., Narod, S. A., & Karlan, B. Y. (2000) · PubMed · Cited by 324 · see citing works
Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2 -Mutated Ovarian Carcinoma
Sakai, W., Swisher, E. M., Jacquemont, C. F., Chandramohan, K. V., Couch, F. J., Langdon, S. P., Wurz, K., Higgins, J., Villegas, E., & Taniguchi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1178 · Cited by 322 · see citing works
Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4–ligase IV during chromosomal translocation formation
Simsek, D., & Jasin, M. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1773 · Cited by 321 · see citing works
Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
Li, M., & Yu, X. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.025 · Cited by 316 · see citing works
Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53 –Mediated Mouse Mammary Tumors
Shafee, N., Smith, C. R., Wei, S., Kim, Y. H., Mills, G. B., Hortobágyi, G. N., Stanbridge, E. J., & Lee, E. Y.-H. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5480 · Cited by 305 · see citing works
MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection
Boersma, V., Moatti, N., Segura‐Bayona, S., Peuscher, M. H., van der Torre, J., Wevers, B. A., Orthwein, A., Durocher, D., & Jacobs, J. J. L. (2015) · Nature · doi:10.1038/nature14216 · Cited by 304 · see citing works
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G. A., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 303 · see citing works
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
Murai, J., Zhang, Y., Morris, J., Ji, J. J., Takeda, S., Doroshow, J. H., & Pommier, Y. G. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 297 · see citing works
ATR: a master conductor of cellular responses to DNA replication stress
Flynn, R. L., & Zou, L. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.09.005 · Cited by 290 · see citing works
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 290 · see citing works
Self-citation
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 286 · see citing works
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
Kennedy, R. D., & D’Andrea, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4171 · Cited by 283 · see citing works
Self-citation
Parp‐1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells
Hochegger, H., Dejsuphong, D., Fukushima, T., Morrison, C. G., Sonoda, E., Schreiber, V., Zhao, G., Saberi, A., Masutani, M., Adachi, N., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601015 · Cited by 276 · see citing works
Classical and Alternative End-Joining Pathways for Repair of Lymphocyte-Specific and General DNA Double-Strand Breaks
Boboilă, C., Alt, F. W., & Schwer, B. (2012) · Advances in immunology · doi:10.1016/b978-0-12-394300-2.00001-6 · Cited by 273 · see citing works
An essential role for CtIP in chromosomal translocation formation through an alternative end-joining pathway
Zhang, Y., & Jasin, M. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1940 · Cited by 269 · see citing works
Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones.
Doroshow, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4514 · Cited by 268 · see citing works
RIF1 Counteracts BRCA1-mediated End Resection during DNA Repair
Feng, L., Fong, K.-W., Wang, J., Wang, W., & Chen, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.457440 · Cited by 267 · see citing works
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
Mukhopadhyay, A., Elattar, A., Cerbinskaite, A., Wilkinson, S. J., Drew, Y., Kyle, S., Los, G., Hostomský, Z., Edmondson, R. J., & Curtin, N. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2758 · Cited by 266 · see citing works
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Johnson, N., Johnson, S. F., Yao, W., Li, Y.-C., Choi, Y.-E., Bernhardy, A. J., Wang, Y., Capelletti, M., Sarosiek, K. A., Moreau, L. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305170110 · Cited by 264 · see citing works
Self-citation
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Soslow, R. A., Han, G., Park, K. J., Garg, K., Olvera, N., Spriggs, D. R., Kauff, N. D., & Levine, D. A. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.183 · Cited by 262 · see citing works
BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., Klijn, C. N., van der Heijden, I., van der Gulden, H. M. L., Wientjens, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.014 · Cited by 261 · see citing works
Biochemical evidence for Ku-independent backup pathways of NHEJ
Wang, H. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg728 · Cited by 260 · see citing works
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas
Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259 · see citing works
Ku Regulates the Non-Homologous End Joining Pathway Choice of DNA Double-Strand Break Repair in Human Somatic Cells
Fattah, F. J., Lee, E. H., Weisensel, N. A., Wang, Y., Lichter, N., & Hendrickson, E. A. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000855 · Cited by 244 · see citing works
Double-strand break repair in Ku86- and XRCC4-deficient cells
Kabotyanski, E. B., Gomelsky, L., Han, J.-O., Roth, D. B., & Stamato, T. D. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.23.5333 · Cited by 244 · see citing works
Synthetic Lethality — A New Direction in Cancer-Drug Development
Iglehart, J. D., & Silver, D. P. (2009) · New England Journal of Medicine · doi:10.1056/nejme0903044 · Cited by 229 · see citing works
Association Between BRCA1 and BRCA2 Mutations and Survival in Women with Invasive Epithelial Ovarian Cancer
Bolton, K., Chenevix-Trench, G., Goh, C., Sadetzki, S., Ramus, S., Karlan, B., Lambrechts, D., Despierre, E., Barrowdale, D., McGuffog, L., et al. (2012) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2012.20 · Cited by 219 · see citing works
PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis
Langelier, M.-F., & Pascal, J. M. (2013) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2013.01.003 · Cited by 215 · see citing works
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Yap, T. A., Sandhu, S. K., Carden, C. P., & Bono, J. S. D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20095 · Cited by 212 · see citing works
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
Joshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551143 · Cited by 201 · see citing works
How do real tumors become resistant to cisplatin?
Borst, P., Rottenberg, S., & Jonkers, J. (2008) · Cell Cycle · doi:10.4161/cc.7.10.5930 · Cited by 192 · see citing works
Different types of V(D)J recombination and end-joining defects in DNA double-strand break repair mutant mammalian cells
Verkaik, N. S., Esveldt, R. E., van Heemst, D., Brüggenwirth, H. T., Hoeijmakers, J. H. J., Zdzienicka, M. Z., & van Gent, D. C. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200203)32:3 · Cited by 189 · see citing works
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Lee, J.-M., Hays, J. L., Annunziata, C. M., Noonan, A. M., Minasian, L. M., Zujewski, J. A., Yu, M., Gordon, N., Ji, J. J., Sissung, T. M., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju089 · Cited by 185 · see citing works
Fanconi anemia pathway–deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated
Kennedy, R. D., Chen, C. C., Stuckert, P., Archila, E. M., la Vega, M. A. D., Moreau, L. A., Shimamura, A., & D’Andrea, A. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31245 · Cited by 174 · see citing works
Self-citation
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
Pettitt, S. J., Rehman, F. L., Bajrami, I., Brough, R., Wållberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061520 · Cited by 173 · see citing works
Targeting the S and G2 checkpoint to treat cancer
Chen, T., Stephens, P., Middleton, F. K., & Curtin, N. J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.009 · Cited by 168 · see citing works
A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy
Kang, J., D’Andrea, A. D., & Kozono, D. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs177 · Cited by 167 · see citing works
Self-citation
Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress
Gagné, J., Pic, É., Isabelle, M., Krietsch, J., Éthier, C., Paquet, É. R., Kelly, I., Boutin, M., Moon, K., Foster, L. J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks486 · Cited by 165 · see citing works
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
Oplustilova, L., Wolanin, K., Mistrík, M., Kořínková, G., Šimková, D., Bouchal, J., Lenobel, R., Bártková, J., Lau, A., O’Connor, M. J., et al. (2012) · Cell Cycle · doi:10.4161/cc.22026 · Cited by 164 · see citing works
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Rajan, A., Carter, C. A., Kelly, R. J., Gutierrez, M. E., Kummar, S., Szabo, E. M., Yancey, M. A., Ji, J. J., Mannargudi, B. M., Woo, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2425 · Cited by 164 · see citing works
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Bouwman, P., & Jonkers, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0225 · Cited by 162 · see citing works
Amplification of 11q13 in ovarian carcinoma
Brown, L. A., Kalloger, S. E., Miller, M. A., Shih, I., McKinney, S. E., Santos, J. L., Swenerton, K., Spellman, P. T., Gray, J. W., Gilks, C. B., et al. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20549 · Cited by 160 · see citing works
Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4Preprint
Guillemette, S., Serra, R. W., Peng, M., Hayes, J. A., Konstantinopoulos, P. A., Green, M. R., & Cantor, S. B. (2015) · Genes & Development · doi:10.1101/gad.256214.114 · Cited by 152 · see citing works
Self-citation
Management strategies for recurrent platinum-resistant ovarian cancer
Naumann, R. W., & Coleman, R. L. (2011) · Drugs · doi:10.2165/11591720-000000000-00000 · Cited by 152 · see citing works
PARP inhibitors in ovarian cancer: Current status and future promise
Liu, J. F., Konstantinopoulos, P. A., & Matulonis, U. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.039 · Cited by 144 · see citing works
Self-citation
Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel
Maede, Y., Shimizu, H., Fukushima, T., Kogame, T., Nakamura, T., Miki, T., Takeda, S., Pommier, Y. G., & Murai, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0551 · Cited by 143 · see citing works
A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants
Bouwman, P., van der Gulden, H., van der Heijden, I., Drost, R., Klijn, C. N., Prasetyanti, P., Pieterse, M., Wientjens, E., Seibler, J., Hogervorst, F. B. L., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0094 · Cited by 140 · see citing works
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Ang, J. E., Gourley, C., Powell, C. B., High, H. A., Shapira‐Frommer, R., Castonguay, V., Grève, J. D., Atkinson, T., Yap, T. A., Sandhu, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1262 · Cited by 139 · see citing works
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
Ceccaldi, R., O’Connor, K. W., Mouw, K. W., Li, A. Y., Matulonis, U. A., D’Andrea, A. D., & Konstantinopoulos, P. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2593 · Cited by 132 · see citing works
Self-citation
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129 · see citing works
VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation of BRCA1 and BRCA2
Lim, J. Y., Yang, K. Y., Taylor‐Harding, B., Wiedemeyer, W. R., & Buckanovich, R. J. (2014) · Neoplasia · doi:10.1016/j.neo.2014.04.003 · Cited by 128 · see citing works
The Role of Mechanistic Factors in Promoting Chromosomal Translocations Found in Lymphoid and Other Cancers
Zhang, Y., Gostissa, M., Hildebrand, D. G., Becker, M. S., Boboilă, C., Chiarle, R., Lewis, S. M., & Alt, F. W. (2010) · Advances in immunology · doi:10.1016/s0065-2776(10)06004-9 · Cited by 123 · see citing works
CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors
Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T., & D’Andrea, A. D. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-24 · Cited by 115 · see citing works
Self-citation
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer
Konstantinopoulos, P. A., Wilson, A. J., Saskowski, J. L., Wass, E., & Khabele, D. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.007 · Cited by 114 · see citing works
Self-citation
Targeting homologous recombination repair defects in cancer
Evers, B., Helleday, T., & Jonkers, J. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.06.001 · Cited by 113 · see citing works
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
Lorenzo, S. B. D., Patel, A. G., Hurley, R. M., & Kaufmann, S. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00228 · Cited by 110 · see citing works
Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes
Patel, A. G., Flatten, K. S., Schneider, P. A., Dai, N. T., McDonald, J. S., Poirier, G. G., & Kaufmann, S. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.296475 · Cited by 107 · see citing works
BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark
Søgaard, M., Kjær, S. K., Cox, M. J., Woźniak, E. L., Høgdall, E. V. S., Høgdall, C. K., Blaakær, J., Jacobs, I. J., Gayther, S. A., & Ramus, S. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4806 · Cited by 105 · see citing works
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
Ruscito, I., Dimitrova, D., Vasconcelos, I. I. M., Gellhaus, K., Schwachula, T., Bellati, F., Zeillinger, R., Benedetti-Panici, P., Vergote, I. B., Mahner, S., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.05.001 · Cited by 103 · see citing works
DNA polymerase POLQ and cellular defense against DNA damage
Yousefzadeh, M. J., & Wood, R. D. (2012) · DNA repair · doi:10.1016/j.dnarep.2012.10.004 · Cited by 102 · see citing works
BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin
Safra, T., Borgato, L., Nicoletto, M. O., Rolnitzky, L. M., Pelles-Avraham, S., Geva, R., Donach, M. E., Curtin, J. P., Novetsky, A. P., Grenader, T., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0272 · Cited by 94 · see citing works
Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
Liu, X., Han, E. K.-H., Anderson, M. G., Shi, Y., Semizarov, D., Wang, G., McGonigal, T. P., Roberts, L., Lasko, L. M., Palma, J. P., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0299 · Cited by 92 · see citing works
Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype
Gourley, C., Michie, C. O., Roxburgh, P., Yap, T. A., Harden, S., Paul, J., Ragupathy, K., Todd, R., Petty, R., Reed, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1082 · Cited by 88 · see citing works
Role of gemcitabine in ovarian cancer treatment
Lorusso, D., Stefano, A. D., Fanfani, F., & Scambia, G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj979 · Cited by 81 · see citing works
MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability
Choi, Y. E., Pan, Y., Park, E., Konstantinopoulos, P. A., De, S., D’Andrea, A. D., & Chowdhury, D. (2014) · eLife · doi:10.7554/elife.02445 · Cited by 74 · see citing works
Self-citation
cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group.
Thigpen, T., Shingleton, H. M., Homesley, H. D., Lagasse, L. D., & Blessing, J. A. (1979) · PubMed · Cited by 74 · see citing works
Competition between PARP-1 and Ku70 control the decision between high-fidelity and mutagenic DNA repair
Paddock, M. N., Bauman, A. T., Higdon, R., Kolker, E., Takeda, S., & Scharenberg, A. M. (2011) · DNA repair · doi:10.1016/j.dnarep.2010.12.005 · Cited by 68 · see citing works
Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study.
Rossof, A. H., Rw, T., Stephens, R., Thigpen, T., Mk, S., Groppe, C. W., Hj, E., & Fisher, R. I. (1979) · PubMed · Cited by 68 · see citing works
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
Choi, Y. E., Battelli, C., Watson, J., Liu, J. F., Curtis, J. D., Morse, A., Matulonis, U. A., Chowdhury, D., & Konstantinopoulos, P. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1929 · Cited by 60 · see citing works
Self-citation
The current treatment of recurrent ovarian cancer
Herzog, T. J. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0074-9 · Cited by 60 · see citing works
Disposition and Drug-Drug Interaction Potential of Veliparib (ABT-888), a Novel and Potent Inhibitor of Poly(ADP-ribose) Polymerase
Li, X., Delzer, J., Voorman, R. L., de Morais, S. M., & Lao, Y. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037820 · Cited by 60 · see citing works
Subtyping Analysis of Fanconi Anemia by Immunoblotting and Retroviral Gene Transfer
Pulsipher, M. A., Kupfer, G. M., Näf, D., Suliman, A., Lee, J.-S., Jakobs, P. M., Grompe, M., Joenje, H., Sieff, C. A., Guinan, E. C., et al. (1998) · Molecular Medicine · doi:10.1007/bf03401752 · Cited by 59 · see citing works
Self-citation
Intraperitoneal Chemotherapy Comes of Age
Cannistra, S. A. (2006) · New England Journal of Medicine · doi:10.1056/nejme058308 · Cited by 56 · see citing works
BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer
Tammaro, C., Raponi, M., Wilson, D. I., & Baralle, D. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120140 · Cited by 51 · see citing works
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study
Weberpals, J. I., Tu, D., Squire, J. A., Amin, M. S., Islam, S., Pelletier, L. B., O'Brien, A. M., Hoskins, P. J., & Eisenhauer, E. A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq770 · Cited by 49 · see citing works
Treating Cancer by Targeting a Weakness
Brody, L. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmcibr052331 · Cited by 43 · see citing works
Oral Etoposide for the Treatment of Recurrent Ovarian Cancer
Ozols, R. F. (1999) · Drugs · doi:10.2165/00003495-199958003-00007 · Cited by 20 · see citing works
Ovarian Cancer: Is Dose Intensity Dead?
Ozols, R. F. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1723 · Cited by 14 · see citing works
Management of Ovarian Cancer
Awtrey, C. S. (2012) · JAMA · doi:10.1001/jama.2012.269 · Cited by 13 · see citing works
Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers.
Strickland, K. C., Howitt, B. E., Rodig, S. J., Ritterhouse, L. L., D’Andrea, A. D., Matulonis, U. A., & Konstantinopoulos, P. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5512 · Cited by 12 · see citing works
Self-citation
215 Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparib
Swisher, E., Brenton, J. D., Kaufmann, S., Oza, A. M., Coleman, R. L., O’Malley, D. M., Konecny, G. E., Ma, L., Harrell, M. I., Visscher, D. W., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70341-7 · Cited by 10 · see citing works
Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors.
Do, K. T., Wilsker, D. F., Balasubramanian, P., Zlott, J., Jeong, W., Lawrence, S. M., Kinders, R. J., Collins, J. M., Chen, A. P., Doroshow, J. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2503 · Cited by 7 · see citing works
Abstract 1788: The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition.
Johnson, S. F., Johnson, N., Chi, D., Primack, B., D’Andrea, A. D., Lim, E., & Shapiro, G. I. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-1788 · Cited by 4 · see citing works
Self-citation

Flagged first, then by citations

2 of the 180 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

[16]Integrated genomic analyses of ovarian carcinoma Nature 2012 474 609 15 PMC3163504 21720365

Sorted by citations

ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197 · see citing works
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M. L., Okamoto, A., Moore, K. N., Ben-Baruch, N. E., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 915 · see citing works
A decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743 · see citing works
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O’Carrigan, B., Jackson, S. P., & Yap, T. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 623 · see citing works
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S. J., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 621 · see citing works
Self-citation
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572 · see citing works
Self-citation
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Noordermeer, S. M., & van Attikum, H. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.07.008 · Cited by 458 · see citing works
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0474 · Cited by 452 · see citing works
Self-citation
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
Mosele, M. F., Westphalen, C. B., Stenzinger, A., Barlési, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 443 · see citing works
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Lin, K., Harrell, M. I., Oza, A. M., Oaknin, A., Ray-Coquard, I. L., Tinker, A. V., Helman, E., Radke, M. R., Say, C., Vo, L.-T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0715 · Cited by 441 · see citing works
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Cruz, C., Castroviejo‐Bermejo, M., Gutiérrez‐Enríquez, S., Llop‐Guevara, A., Ibrahim, Y. H., Gris‐Oliver, A., Bonache, S., Morancho, B., Bruna, A., Rueda, O. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy099 · Cited by 437 · see citing works
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Colombo, N., Sessa, C., du Bois, A., Ledermann, J. A., McCluggage, W. G., McNeish, I. A., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I. B., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000308 · Cited by 415 · see citing works
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kondrashova, O., Nguyen, M., Shield‐Artin, K., Tinker, A. V., Teng, N. N. H., Harrell, M. I., Kuiper, M. J., Ho, G., Barker, H. E., Jasin, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0419 · Cited by 410 · see citing works
Clinical and translational advances in ovarian cancer therapy
Konstantinopoulos, P. A., & Matulonis, U. A. (2023) · Nature Cancer · doi:10.1038/s43018-023-00617-9 · Cited by 399 · see citing works
Self-citation
Ovarian Cancer: A Heterogeneous Disease
Kossaï, M., Leary, A. F., Scoazec, J., & Genestie, C. (2017) · Pathobiology · doi:10.1159/000479006 · Cited by 391 · see citing works
Multifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics
Zhao, S., Yu, X., Qian, Y., Chen, W., & Shen, J. (2020) · Theranostics · doi:10.7150/thno.42564 · Cited by 391 · see citing works
Ovarian Cancer Immunotherapy and Personalized Medicine
Morand, S. M., Devanaboyina, M., Staats, H., Stanbery, L., & Nemunaitis, J. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126532 · Cited by 383 · see citing works
PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer
Hong, T., Lei, G., Chen, X., Li, H., Zhang, X., Wu, N., Zhao, Y., Zhang, Y., & Wang, J. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101928 · Cited by 381 · see citing works
The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication
Tarsounas, M., & Sung, P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0218-z · Cited by 366 · see citing works
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors
Zhou, J., Gelot, C., Pantelidou, C., Li, A. Y., Yücel, H., Davis, R. E., Färkkilä, A., Kochupurakkal, B. S., Syed, A., Shapiro, G. I., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00203-x · Cited by 353 · see citing works
Self-citation
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Ledermann, J. A., Matías‐Guiu, X., Amant, F. C., Concin, N., Davidson, B., Fotopoulou, C., González-Martı́n, A., Gourley, C., Leary, A. F., Lorusso, D., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.015 · Cited by 353 · see citing works
Ovarian Cancer
Caruso, G., Weroha, S. J., & Cliby, W. A. (2025) · JAMA · doi:10.1001/jama.2025.9495 · Cited by 349 · see citing works
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
Rondinelli, B., Gogola, E., Yücel, H., Duarte, A. A., van de Ven, M., van der Sluijs, R., Konstantinopoulos, P. A., Jonkers, J., Ceccaldi, R., Rottenberg, S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3626 · Cited by 332 · see citing works
Self-citation
Biomarkers for Homologous Recombination Deficiency in Cancer
Hoppe, M. M., Sundar, R., Tan, D. S. P., & Jeyasekharan, A. D. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy085 · Cited by 329 · see citing works
Ovarian cancer mutational processes drive site-specific immune evasion
Vázquez-Garćıa, I., Uhlitz, F., Ceglia, N., Lim, J. L., Wu, M. K. Y., Mohibullah, N., Niyazov, J., Ruiz, A. E. B., Boehm, K. M., Bojilova, V., et al. (2022) · Nature · doi:10.1038/s41586-022-05496-1 · Cited by 318 · see citing works
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Damia, G. L. M., & Broggini, M. (2019) · Cancers · doi:10.3390/cancers11010119 · Cited by 297 · see citing works
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Castroviejo‐Bermejo, M., Cruz, C., Llop‐Guevara, A., Gutiérrez‐Enríquez, S., Ducy, M., Ibrahim, Y. H., Gris‐Oliver, A., Pellegrino, B., Bruna, A., Guzmán, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809172 · Cited by 273 · see citing works
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Wang, Q., Bergholz, J. S., Ding, L., Lin, Z., Kabraji, S. K., Hughes, M. E., He, X., Xie, S., Jiang, T., Wang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30568-1 · Cited by 272 · see citing works
Self-citation
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30905-7 · Cited by 263 · see citing works
Self-citation
Microhomology-mediated end joining: Good, bad and ugly
Seol, J.-H., Shim, E. Y., & Lee, S. E. (2017) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2017.07.002 · Cited by 249 · see citing works
Keeping the senescence secretome under control: molecular reins on the senescence-associated secretory phenotype.
Malaquin, N., Martinez, A., & Rodier, F. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.05.010 · Cited by 247 · see citing works
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
Riaz, N., Blecua, P., Lim, R. S., Shen, R., Higginson, D. S., Weinhold, N., Norton, L., Weigelt, B., Powell, S. N., & Reis-Filho, J. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00921-w · Cited by 246 · see citing works
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors
Kristeleit, R. S., Shapiro, G. I., Burris, H. A., Oza, A. M., LoRusso, P. M., Patel, M. R., Domchek, S. M., Balmañà, J., Drew, Y., Chen, L.-M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2796 · Cited by 244 · see citing works
Self-citation
Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition
Yang, L., Zhang, Y., Shan, W., Hu, Z., Yuan, J., Pi, J., Wang, Y., Fan, L., Tang, Z., Li, C., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal1645 · Cited by 243 · see citing works
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
Park, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M., Balachandran, V. P., McIntyre, C. A., Dika, I. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0418 · Cited by 238 · see citing works
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Fang, Y., McGrail, D. J., Sun, C., Labrie, M., Chen, X., Zhang, D., Ju, Z., Vellano, C. P., Lu, Y., Li, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.001 · Cited by 237 · see citing works
Biomarker-Guided Development of DNA Repair Inhibitors
Cleary, J. M., Aguirre, A. J., Shapiro, G. I., & D’Andrea, A. D. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.035 · Cited by 231 · see citing works
Self-citation
A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening
Beshiri, M. L., Tice, C. M., Tran, C., Nguyen, H. M., Sowalsky, A. G., Agarwal, S., Jansson, K. H., Yang, Q., McGowen, K. M., Yin, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0409 · Cited by 228 · see citing works
Towards precision oncology in advanced prostate cancer
Ku, S., Gleave, M. E., & Beltran, H. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0237-8 · Cited by 227 · see citing works
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Konstantinopoulos, P. A., Cheng, S., Hendrickson, A. E. W., Penson, R. T., Schumer, S., Doyle, L. A., Lee, E. K., Kohn, E. C., Duska, L., Crispens, M. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30180-7 · Cited by 226 · see citing works
Self-citation
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
Konecny, G. E., & Kristeleit, R. S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.311 · Cited by 218 · see citing works
PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Bitler, B. G., Watson, Z. L., Brubaker, L. W., & Behbakht, K. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.10.003 · Cited by 218 · see citing works
PARP inhibitors in ovarian cancer
Franzese, E., Centonze, S., Diana, A., Carlino, F., Guerrera, L. P., Napoli, M. D., Vita, F. D., Pignata, S., Ciardiello, F., & Orditura, M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.002 · Cited by 214 · see citing works
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Lheureux, S., Cristea, M. C., Bruce, J. P., Garg, S., Cabanero, M., Mantia-Smaldone, G. M., Olawaiye, A. B., Ellard, S. L., Weberpals, J. I., Hendrickson, A. E. W., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32554-x · Cited by 214 · see citing works
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
Sanij, E., Hannan, K. M., Xuan, J., Yan, S., Ahern, J., Trigos, A., Brajanovski, N., Son, J., Chan, K. T., Kondrashova, O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16393-4 · Cited by 210 · see citing works
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
Petropoulos, M., Karamichali, A., Rossetti, G. G., Freudenmann, A., Iacovino, L. G., Dionellis, V. S., Sotiriou, S. K., & Halazonetis, T. D. (2024) · Nature · doi:10.1038/s41586-024-07217-2 · Cited by 209 · see citing works
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
Lee, J., Nair, J. R., Zimmer, A. S., Lipkowitz, S., Annunziata, C. M., Merino, M. J., Swisher, E. M., Harrell, M. I., Trepel, J. B., Lee, M.-J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30009-3 · Cited by 207 · see citing works
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Swisher, E. M., Kwan, T. T., Oza, A. M., Tinker, A. V., Ray-Coquard, I. L., Oaknin, A., Coleman, R. L., Aghajanian, C. A., Konecny, G. E., O’Malley, D. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22582-6 · Cited by 204 · see citing works
Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
de Jonge, M. M., Auguste, A., van Wijk, L. M., Schouten, P. C., Meijers, M., ter Haar, N. T., Smit, V. T. H. B. M., Nout, R. A., Glaire, M. A., Church, D. N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1443 · Cited by 202 · see citing works
Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
Takaya, H., Nakai, H., Takamatsu, S., Mandai, M., & Matsumura, N. (2020) · Scientific Reports · doi:10.1038/s41598-020-59671-3 · Cited by 202 · see citing works
FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair
Kais, Z., Rondinelli, B., Holmes, A. L., O’Leary, C., Kozono, D., D’Andrea, A. D., & Ceccaldi, R. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.031 · Cited by 198 · see citing works
Self-citation
Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
Testa, U., Petrucci, E., Pasquini, L., Castelli, G., & Pelosi, E. (2018) · Medicines · doi:10.3390/medicines5010016 · Cited by 189 · see citing works
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Laniti, D. D., & Coukos, G. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00503-z · Cited by 186 · see citing works
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Jiang, X., Li, X., Li, W., Bai, H., & Zhang, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14133 · Cited by 178 · see citing works
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
Sun, K., Mikule, K. W., Wang, Z., Poon, G. K., Vaidyanathan, A., Smith, G. C., Zhang, Z.-Y., Hanke, J. H., Ramaswamy, S., & Wang, J. (2018) · Oncotarget · doi:10.18632/oncotarget.26354 · Cited by 176 · see citing works
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 170 · see citing works
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Kristeleit, R. S., Lisyanskaya, A., Fedenko, A., Dvorkin, M., de Melo, A. C., Shparyk, Y., Rakhmatullina, I., Bondarenko, I., Colombo, N., Svintsitskiy, V., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00122-x · Cited by 163 · see citing works
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
Waks, A. G., Cohen, O., Kochupurakkal, B. S., Kim, D., Dunn, C. E., Buendia, J., Wander, S. A., Helvie, K. E., Lloyd, M. R., Marini, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.008 · Cited by 162 · see citing works
Self-citation
DNA-PKcs: A Multi-Faceted Player in DNA Damage Response
Yue, X., Bai, C., Xie, D., Ma, T., & Zhou, P. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.607428 · Cited by 160 · see citing works
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
George, A., Kaye, S., & Banerjee, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.191 · Cited by 158 · see citing works
PARP Inhibitors in Ovarian Cancer
Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666180305165256 · Cited by 158 · see citing works
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 157 · see citing works
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
Lallo, A., Frese, K. K., Morrow, C. J., Sloane, R. A. S., Gulati, S., Schenk, M. W., Trapani, F., Simms, N., Galvin, M., Brown, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2805 · Cited by 156 · see citing works
Drugging the addict: non‐oncogene addiction as a target for cancer therapy
Nagel, R., Semenova, E. A., & Berns, A. J. M. (2016) · EMBO Reports · doi:10.15252/embr.201643030 · Cited by 153 · see citing works
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Zeng, M., Kwiatkowski, N. P., Zhang, T., Nabet, B., Xu, M., Liang, Y., Quan, C., Wang, J., Hao, M., Palakurthi, S. S., et al. (2018) · eLife · doi:10.7554/elife.39030 · Cited by 152 · see citing works
Self-citation
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Lheureux, S., Lai, Z., Dougherty, B. A., Runswick, S. K., Hodgson, D., Timms, K. M., Lanchbury, J. S. S., Kaye, S. B., Gourley, C., Bowtell, D. D. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2615 · Cited by 151 · see citing works
EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition
Karakashev, S. V., Fukumoto, T., Zhao, B., Lin, J., Wu, S., Fatkhutdinov, N., Park, P. H., Semenova, G., Jean, S., Cadungog, M. G., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.015 · Cited by 151 · see citing works
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0247 · Cited by 146 · see citing works
Self-citation
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Parmar, K., Kochupurakkal, B. S., Lazaro, J., Wang, Z. C., Palakurthi, S. S., Kirschmeier, P. T., Yang, C., Sambel, L. A., Färkkilä, A., Reznichenko, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0448 · Cited by 143 · see citing works
Self-citation
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer
Choi, Y. E., Meghani, K. A., Brault, M. E., Leclerc, L., He, Y. J., Day, T. A., Elias, K. M., Drapkin, R., Weinstock, D. M., Dao, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.046 · Cited by 142 · see citing works
Self-citation
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
Bruand, M., Barras, D., Mina, M., Ghisoni, E., Morotti, M., Lanitis, E., Fahr, N., Desbuisson, M., Grimm, A. J., Zhang, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109412 · Cited by 141 · see citing works
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Boussios, S., Abson, C., Moschetta, M., Rassy, E., Karathanasi, A., Bhat, T., Ghumman, F. I. A., Sheriff, M., & Pavlidis, N. A. (2020) · Drugs in R&D · doi:10.1007/s40268-020-00301-8 · Cited by 140 · see citing works
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments
Marchetti, C., De Felice, F., Romito, A., Iacobelli, V., Sassu, C. M., Corrado, G., Ricci, C., Scambia, G., & Fagotti, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.011 · Cited by 139 · see citing works
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
Zheng, F., Zhang, Y., Chen, S., Weng, X., Rao, Y., & Hongmei, F. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109661 · Cited by 138 · see citing works
Mechanisms and Targets Involved in Dissemination of Ovarian Cancer
Weidle, U. H., Birzele, F., Kollmorgen, G., & Rueger, R. (2016) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20004 · Cited by 137 · see citing works
Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition
Haynes, B. M., Murai, J., & Lee, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.003 · Cited by 137 · see citing works
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Ngoi, N. Y. L., & Tan, D. S. P. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100144 · Cited by 137 · see citing works
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy
Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E., Assatova, B., Casado, J., Meinsohn, M.-C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0818 · Cited by 136 · see citing works
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
Harter, P., Hauke, J., Heitz, F., Reuß, A., Kommoss, S., Marmé, F., Heimbach, A., Prieske, K., Richters, L., Burges, A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186043 · Cited by 135 · see citing works
Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer
Freimund, A. E., Beach, J. A., Christie, E. L., & Bowtell, D. D. L. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.007 · Cited by 135 · see citing works
The lysine‐specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer
Rampias, T. N., Karagiannis, D., Avgeris, M., Polyzos, A., Kokkalis, A., Kanaki, Z., Kousidou, E., Tzetis, M., Kanavakis, E., STRAVODIMOS, K. G., et al. (2019) · EMBO Reports · doi:10.15252/embr.201846821 · Cited by 134 · see citing works
A PET imaging agent for evaluating PARP-1 expression in ovarian cancer
Makvandi, M., Pantel, A. R., Schwartz, L. E., Schubert, E. K., Xu, K., Hsieh, C., Hou, C., Kim, H., Weng, C.-C., Winters, H. D., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97992 · Cited by 130 · see citing works
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
Bian, X., Gao, J., Luo, F., Rui, C., Zheng, T., Wang, D., Wang, Y., Roberts, T. M., Liu, P., Zhao, J. J., et al. (2017) · Oncogene · doi:10.1038/onc.2017.326 · Cited by 124 · see citing works
Targeted nanomedicine in cisplatin-based cancer therapeutics
Han, Y., Wen, P., Li, J., & Kataoka, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.049 · Cited by 123 · see citing works
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Rocconi, R. P., Grosen, E. A., Ghamande, S. A., Chan, J. K., Barve, M. A., Oh, J., Tewari, D. S., Morris, P. C., Stevens, E., Bottsford-Miller, J. N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30533-7 · Cited by 122 · see citing works
Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
Póti, Á., Gyergyák, H., Németh, E., Rusz, O., Tóth, S., Kovácsházi, C., Chen, D., Szikriszt, B., Spisák, S., Takeda, S., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1867-0 · Cited by 116 · see citing works
The complementarity of DDR, nucleic acids and anti-tumour immunity
Kornepati, A. V. R., Rogers, C. M., Sung, P., & Curiel, T. J. (2023) · Nature · doi:10.1038/s41586-023-06069-6 · Cited by 115 · see citing works
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
Jiang, X., Li, W., Li, X., Bai, H., & Zhang, Z. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200524 · Cited by 113 · see citing works
Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
Mekonnen, N., Yang, H., & Shin, Y. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880643 · Cited by 113 · see citing works
PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers
Murai, J., & Pommier, Y. G. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055914 · Cited by 112 · see citing works
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Chiappa, M., Guffanti, F., Bertoni, F., Colombo, I., & Damia, G. L. M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100744 · Cited by 112 · see citing works
Topoisomerase I inhibitors: Challenges, progress and the road ahead
Talukdar, A., Kundu, B., Sarkar, D., Goon, S., & Mondal, M. A. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114304 · Cited by 111 · see citing works
Clinical assays for assessment of homologous recombination DNA repair deficiency
Stover, E. H., Fuh, K. C., Konstantinopoulos, P. A., Matulonis, U. A., & Liu, J. F. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.029 · Cited by 109 · see citing works
Self-citation
Multiple roles of DNA2 nuclease/helicase in DNA metabolism, genome stability and human diseases
Zheng, L., Meng, Y., Campbell, J. L., & Shen, B. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1101 · Cited by 108 · see citing works
A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients
Tumiati, M., Hietanen, S., Hynninen, J., Pietilä, E. A., Färkkilä, A., Kaipio, K., Roering, P., Huhtinen, K., Alkodsi, A., Li, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3770 · Cited by 106 · see citing works
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Evans, T., & Matulonis, U. A. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016687254 · Cited by 105 · see citing works
Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
Gralewska, P., Gajek, A., Marczak, A., & Rogalska, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00874-6 · Cited by 105 · see citing works
PARP1: Structural insights and pharmacological targets for inhibition
Spiegel, J. O., Houten, B. V., & Durrant, J. D. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103125 · Cited by 104 · see citing works
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials
Zhou, J., Feng, L. J., & Zhang, X. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s147726 · Cited by 103 · see citing works
CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity
Karakashev, S. V., Zhu, H., Wu, S., Yokoyama, Y., Bitler, B. G., Park, P. H., Lee, J., Kossenkov, A. V., Gaonkar, K. S., Yan, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03031-3 · Cited by 102 · see citing works

How to measure homologous recombination deficiency in ovarian cancer
Marchetti, C., & McNeish, I. A. (2017) · Cancer Breaking News · doi:10.19156/cbn.2017.0034 · Cited by 2 · see citing works
Homologous Recombination and BRCA Genes in Ovarian Cancer
Liu, J. F., & Konstantinopoulos, P. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803741-6.00006-9 · Cited by 1 · see citing works
Self-citation
Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data
Chartron, E., Theillet, C. G., Guiu, S., & Jacot, W. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.012 · Cited by 39 · see citing works
Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction
Chiang, Y., Lin, P., & Cheng, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675972 · Cited by 38 · see citing works
Abstract IA14: Exploiting the translational and functional opportunities for homologous recombination deficiency
Edmondson, R. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ovca13-ia14

Authors: Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D.
Affiliations: Harvard University (US)
2Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Corresponding author: Konstantinopoulos, Panagiotis A.
ORCID: Konstantinopoulos, Panagiotis A.
Shapiro, Geoffrey I.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-11-01
Volume: 5
Issue: 11
Pages: 1137-1154
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-15-0714
PMC: PMC4631624
OpenAlex: W2179105349
Cited by: 945
References: 180
Citations by year: 2026: 67 · 2025: 97 · 2024: 109 · 2023: 126 · 2022: 115 · 2021: 102 · 2020: 100 · 2019: 74 · 2018: 74 · 2017: 54 · 2016: 27
FWCI: 5.56
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA090687, UM1CA186709, P50CA168504)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
Keywords: homologous recombination deficiency, epithelial ovarian cancer, DNA repair deficiency, PARP inhibitors, synthetic lethality, platinum analogues, high-grade serous ovarian cancer, drug resistance, targeted therapy
MeSH terms: Carcinoma, Ovarian Epithelial, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, DNA Repair, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Phenotype, Genetic Variation, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Treatment Outcome, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Homologous Recombination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks